Personalised patient solutions with CBD
Approved standard therapies do not always provide the desired patient benefit. In March 2018, the portfolio was expanded to include a GMP-compliant cannabidiol (CBD) produced synthetically in Germany.
Cannabidiol offers doctors an additional option within the scope of their therapeutic freedom. It is specially designed for dispensing and compounding in pharmacies and fully complies with the requirements of Section 6 (3) of the German Pharmacy Operating Regulations (ApoBetrO).